Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts
Wei-Hung Yang1,2,3,4, Shan-Chi Liu5, Chun-Hao Tsai6,7, Yi-Chin Fong3,7, Shoou-Jyi Wang8, Yung-Sen Chang1, and Chih-Hsin Tang9,10,11*
1Department of Orthopedic Surgery, Taichung Hospital, Department of Health Executive Yuan, Taichung, Taiwan
2Department of Nursing, National Taichung University of Science and Technology, Taichung, Taiwan
3School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
4Graduate Institute of Biotechnology, National Chung Hsing University, Taichung, Taiwan 5Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan 6Department of Medicine and Graduate Institute of Clinical Medical Science, China
Medical University, Taichung, Taiwan
7Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan
8Department of Orthopedic Surgery, Chang-Hua Hospital, Department of Health Executive Yuan, Changhua Country, Taiwan
9Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan
10Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan
11Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan
*: Author for Correspondence: Chih-Hsin, Tang PhD
Graduate Institute of Basic Medical Science, China Medical University No. 91, Hsueh-Shih Road, Taichung, Taiwan
Tel: (886) 4-22052121 Ext. 7726. Fax: (886)4-22333641. E-mail: [email protected] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Abstract
Background Leptin, an adipocyte-secreted hormone that centrally regulates weight control, may exert proinflammatory effects in the joint, depending on the immune response. Leptin is abundantly expressed in osteoarthritis (OA) cartilage and synovium. However, the relationship between leptin and interleukin-6 (IL-6) in OA synovial fibroblasts (OASFs) remains obscure.
Methodology/Principal Findings Stimulation of OASFs with leptin induced IL-6 expression in a concentration- and time-dependent manner. OASFs expressed the long (OBRl) and short (OBRs) isoforms of the leptin receptor. However, OBRl, but not OBRs, antisense oligonucleotide (AS-ODN) abolished the leptin-mediated increase of IL-6 expression. Transfection with insulin receptor substrate (IRS)-1 siRNA decreased leptin-induced IL-6 production. In addition, pretreatment of cells with PI3K, Akt, or AP-1 inhibitor also inhibited the potentiating action of leptin. Leptin-induced AP-1 activation was inhibited by OBRl, IRS-1, PI3K, or Akt inhibitors and siRNAs.
Conclusions/Significance Our results showed that leptin activates the OBRl receptor, which in turn activates IRS-1, PI3K, Akt, and AP-1 pathway, leading to up-regulation of IL-6 expression.
Running title: Leptin induces IL-6 production
Key words: Leptin; OBRl; IL-6; Osteoarthritis; IRS-1 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
Introduction
Osteoarthritis (OA) is the most common adult joint disease, and is increasing in frequency and severity . The cause of OA is not yet fully understood. However, obesity, inflammation of the joints, repetitive motion, and genetic predisposition are considered to contribute to excessive loading of the joints, leading to the onset of the disease . To response the proinflammatory mediators produced by chondrocytes and macrophages, osteoarthritis synovial fibroblasts (OASFs) produce cytokines that
promote cartilage degradation, neovascularization, and inflammation.
The development and progression of OA are now believed to involve inflammation , and elevated levels of cytokines, such as interleukin-6 (IL-6) also seems to be the main proinflammatory cytokine involved in the pathophysiology of OA . IL-6 has numerous biological activities and is considered as the major player that regulates the innate immune response, haemopoiesis, and inflammation . A previous report showed the concentration of IL-6 to be increased in sera and synovial fluid from OA patients . Combination treatment with IL-1β and oncostatin was found to up-regulate IL-6, MMP-1, and MMP-13 in human cartilage . In addition, mechanical injury could potentiate the effects of IL-6 on proteoglycan degradation , while treatment of chondrocytes with IL-6 reduced the expression of type II collagen . A clinical trial in OA patients showed that IL-6 was associated with an risk of cartilage loss . These findings strongly indicate an important role of IL-6 production during OA pathogenesis.
Leptin, a small (16-kDa) nonglycosylated peptide hormone encoded by the obese (ob) gene , is produced predominantly in white adipose tissue . Leptin is an anorexic peptide that is primarily known for its role as a hypothalamic modulator of food intake, body weight, and fat stores . The biological activity of leptin is mediated by specific receptors (OBR), which are located in several tissues throughout the body . At least 6 isoforms of OBR are generated by alternative messenger RNA splicing, but in humans, 2 major forms of leptin receptor are expressed. The long form of the receptor (OBRl), which is believed to be the signaling-competent receptor isoform, is essential in mediating most of the biological effects of leptin . The signaling pathways activated by OBRl include the classic cytokine JAK2/STAT3 pathway as well as the insulin receptor substrate (IRS)-1/PI3K/Akt pathway .
The potential role of leptin in OA is supported by the relationship between high body mass index and an increased risk of OA . Leptin has been detected also in synovial fluid obtained from patients with OA . In experimental models, leptin may display proinflammatory effects in the joint, depending on the immune response . Therefore, leptin can be easily considered as having a prototypical proinflammatory and catabolic role in cartilage metabolism and progression of OA. Nevertheless, the 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96
current understanding of the role of leptin in synovial fibroblasts and OA progression is still incomplete. Here, we explored the signaling pathway involved in leptin-induced IL-6 production in human OASFs. The results showed that leptin activates the OBRl receptor, which in turn activates IRS-1, PI3K, Akt, and AP-1 pathway, leading to up-regulation of IL-6 expression.
Materials and methods Materials
Rabbit polyclonal antibody specific for p-IRS-1 was purchased from Cell Signaling and Neuroscience (Danvers, MA). Anti-mouse and anti-rabbit IgG-conjugated horseradish peroxidase and rabbit polyclonal antibodies specific for β-actin, IRS-1, p-p110, p110, p-Akt, Akt, p-c-Jun, and c-Jun were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) The recombinant human leptin and IL-6 ELISA kit were purchased from PeproTech (Rocky Hill, NJ). The AP-1 luciferase plasmid was purchased from Stratagene (La Jolla, CA). Curcumin was purchased from Biomol (Butler Pike, PA). The human IL-6 promoter construct pIL6-luc651(651/+1), AP-1 site mutation (pIL6-luc651ΔAP-1), NF-κB site mutation (pIL6-luc651ΔNF-κB), and C/EBP-β site mutation (pIL6-luc651ΔC/EBP-β) were provided by Dr. O. Eickelberg (Department of Medicine II, University of Giessen, Giessen, Germany). The pSV-β-galactosidase vector and luciferase assay kit were purchased from Promega (Madison, WI). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
The study was approved by the Institutional Review Board of China Medical University Hospital, and informed written consent was obtained from patients. Human synovial fibroblasts were isolated by collagenase treatment of synovial tissue samples obtained from 8 patients with OA during knee replacement surgeries (Patient
information as shown in supplemental data Table S1). OASFs were isolated, cultured,
and characterized as previously described . Cells were amplified during 1 to 3 passages, and the experiments were performed using cells from passages 3 to 6. Transfection of siRNAs
ON-TARGETplus siRNAS targeting IRS-1, p110, Akt, c-Jun, and control were purchased from Dharmacon Research (Lafayette, CO). Transient transfection of 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133
siRNAs was carried out using DharmaFECT1 transfection reagent. siRNA (100 nM) was formulated with DharmaFECT1 transfection reagent according to the manufacturer’s instructions.
Quantitative real-time PCR
Total RNA was extracted from synovial fibroblasts by using a TRIzol kit (MDBio Inc., Taipei, Taiwan). The reverse transcription reaction was performed using 2 µg of total RNA, which was reverse-transcribed into cDNA using oligo(dT) primer . Quantitative real-time PCR (qPCR) analysis was carried out using TaqMan One-Step PCR Master Mix (Applied Biosystems, Foster City, CA). cDNA templates (2 µl) were added per 25-µl reaction with sequence-specific primers and TaqMan probes. Sequences for all target gene primers and probes were purchased commercially (β-actin was used as an internal control) (Applied Biosystems). The qPCR assays were carried out in triplicate on a StepOnePlus sequence detection system. The cycling conditions involved 10-min polymerase activation at 95 °C, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. The threshold was set above the non-template control background and within the linear phase of the target gene amplification to calculate the cycle number at which the transcript was detected (denoted CT).
Western blot analysis
Cellular lysates were prepared as described previously . Proteins were resolved on SDS-PAGE and transferred onto Immobilon polyvinyldifluoride (PVDF) membranes. The blots were blocked with 4% BSA for 1 h at room temperature and then probed with rabbit anti-human antibodies against IRS-1, p110, Akt, or c-Jun (1:1000) for 1 h at room temperature. After 3 washes, the blots were subsequently incubated with donkey anti-rabbit peroxidase-conjugated secondary antibody (1:3000) for 1 h at room temperature. The blots were visualized by enhanced chemiluminescence with Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY). Measurement of IL-6 production
Human synovial fibroblasts were cultured in 24-well culture plates. At confluence, cells were treated with leptin and then incubated in a humidified incubator at 37°C for 24 h. For examination of the downstream signaling pathways involved in leptin treatment, cells were pretreated with various inhibitors for 30 min before leptin (3 M) administration. After incubation, the medium was removed and stored at 80°C until assay. IL-6 in the medium was assayed using the IL-6 enzyme immunoassay kits according to the procedure described by the manufacturer .
134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171
Transfection and reporter gene assay
Human synovial fibroblasts were cotransfected with 0.8 μg of luciferase plasmid and 0.4 μg of β-galactosidase expression vector. OASFs were grown to 80% confluence in 12-well plates and were transfected on the following day with Lipofectamine 2000 (LF2000; Invitrogen). DNA and LF2000 were premixed for 20 min and then applied to the cells. After 24 h of transfection, the cells were incubated with the indicated agents. After further 24-h incubation, the media wereremoved and cells were washed once with cold PBS. To prepare lysates, 100 μl of reporter lysis buffer (Promega, Madison, WI) was added to each well, and cells were scraped from the dishes. The supernatant was collected after centrifugation at 13,000 rpm for 2 min. Aliquots of cell lysates (20 μl) containing equal amounts of protein (20–30 μg) were placed into wells of an opaque black 96-well microplate. An equal volume of luciferase substrate was added to all samples, and luminescence was measured using a microplate luminometer. The luciferase activity was normalized to the transfection efficiency monitored by the cotransfected β-galactosidase expressionvector.
Synthesis of OBRl and OBRs decoy oligonucleotide
We used a phosphorothioate double-stranded decoy oligonucleotide (ODN) carrying the OBRl antisense ODN (AS-ODN; AGACCGAGCGGGCGTTAA) and missense ODN (MM-ODN; AGCCCGCGCGAGTGTTCA) (GenBank accession no. U43168) and the OBRs AS-ODN (TTGTCTTGCCGACCACCA) and MM-ODN (TTATCTTACCAACCGCCA) (GenBank accession no. U50748). ODN (5 μM) was mixed with LF2000 (10 μg/ml) for 30 min at room temperature, and the mixture was added to cells in serum-free medium. After 24 h of transient transfection, the cells were used for the following experiments.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed as described previously . DNA immunoprecipitated with c-Jun antibody was purified and extracted with phenol-chloroform. The purified DNA pellet was subjected to PCR. PCR products were then resolved by 1.5% agarose gel electrophoresis and visualized with UV light. The primers GAACTGACCTGACTTACATA-3′ and 5′-TTGAGACTCATGGGAAAATCC-3′ were used to amplify the human IL-6 promoter region containing the AP-1 binding site (−312 to −39).
Statistical Analysis
Data were expressed as means ± S.E. Statistical analysis was performed with 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209
GraphPad Prism 4. Analysis of variance (ANOVA) and unpaired 2-tailed Student’s t test were used to determine the significant differences between the means. p 0.05 was considered significant.
Results
Leptin induces IL-6 expression in human synovial fibroblasts through OBRl receptor
Leptin is significantly higher in synovial fluid of patients with OA and rheumatoid arthritis (RA) . It has been also reported that leptin plays an important role during OA pathogenesis . Therefore, we used human synovial fibroblasts to investigate the signaling pathways of leptin in the production of IL-6 (an important inflammatory cytokine). Treatment of OASFs with leptin (0.1–3 M) for 24 h induced IL-6 mRNA and protein expression in a concentration-dependent manner, as shown by qPCR and ELISA assay (Fig. 1A and B). In addition, leptin also increased IL-6 mRNA and protein expression dose-dependently (Fig. 1C and D). These data indicate that leptin increased IL-6 expression in human OASFs. Leptin increased IL-6 expression to a similar extent as IL-1 (Supplementary Figure S1). Further work is needed to determine whether leptin has an equal effect in vivo as that shown for IL-1
previously. Previous studies have shown that leptin exerts their cell functions through
interaction with specific leptin receptors OBRl and OBRs . We therefore hypothesized that leptin receptors may be involved in leptin-mediated IL-6 expression in OASFs. Treatment of OASFs with leptin for 24 h significantly increased the mRNA levels of OBRl, whereas OBRs receptor mRNA remained unchanged (Fig. 1E). We next examined whether leptin receptors are involved in the leptin-mediated increase of IL-6 production. Transfection with OBRl or OBRs antisense oligonucleotide (AS-ODN) specifically inhibited OBRl or OBRs expression, respectively (Fig. 1F). In addition, OBRl AS-ODN, but not with OBRl MM-ODN, OBRs AS-ODN, or OBRs MM-ODN, abolished the leptin-induced IL-6 production (Fig. 1G and H). Therefore, OBRl receptor plays a key role in leptin induced IL-6 expression in OASFs.
The IRS-1 and PI3K signaling pathways are involved in leptin-mediated increase of IL-6 expression
Previous studies have shown that leptin induced IRS-1-associated PI3K activity to regulate cell functions . To identify whether IRS-1 is involved in leptin-triggered 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245
IL-6 production, we used IRS-1 siRNA. Transfection of OASFs with IRS-1 siRNA specifically reduced leptin-induced IL-6 expression (Fig. 2A and B). To directly confirm the crucial role of IRS-1 in IL-6 production, we then directly measured the phosphorylation of IRS-1 in response to leptin. Treatment of OASFs with leptin significantly increased IRS-1 phosphorylation (Fig. 2C). Transfection of cells with OBRl AS-ODN, but not with OBRl MM-ODN, reduced the leptin-induced IRS-1 phosphorylation (Fig. 2D). These results show that leptin seems to act through an OBRl- and IRS-1-dependent signaling pathway to enhance IL-6 production in human synovial fibroblasts. We next examined whether PI3K, a critical downstream target of IRS-1 , is involved in leptin-triggered IL-6 production in OASFs. Pretreatment of synovial fibroblasts with specific PI3K inhibitors Ly294002 and wortmannin for 30 min or transfection with p110 siRNA for 24 h markedly decreased the leptin-induced IL-6 production (Fig. 3A and B). We then directly measured the phosphorylation of PI3K in response to leptin. Indeed, treatment of fibroblasts with leptin resulted in a time-dependent phosphorylation of p110 (Fig. 3C). Furthermore, transfection of cells with IRS-1 siRNA reduced the leptin-induced p110 phosphorylation (Fig. 3D). Taken together, these results indicate that leptin increased IL-6 expression in human OASFs via the IRS-1 and PI3K signaling pathway.
The Akt signaling pathway is involved in the potentiating action of leptin
The serine/threonine kinase Akt, a downstream effector of PI3K, is involved in the regulation of cell growth, differentiation, adhesion, and inflammatory reactions . We thus investigated the role of Akt in mediating leptin-induced IL-6 expression by using the Akt inhibitor and Akt siRNA. As shown in Figure 4A and B, leptin-induced IL-6 expression was markedly decreased by pretreatment of cells for 30 min with Akt inhibitor or transfection of cells with Akt siRNA for 24 h. Furthermore, stimulation of OASFs with leptin resulted in time-dependent phosphorylation of Akt (Fig. 4C). We next evaluated the relationship between IRS-1/PI3K and Akt in the leptin-mediated signaling pathway, and found that transfection of cells with IRS-1 siRNA or pretreatment of cells with Ly294002 reduced the leptin-induced Akt phosphorylation (Fig. 4D). These results indicate that leptin appears to act via the IRS-1, PI3K, and Akt signaling pathway to enhance IL-6 production in human OASFs.
Involvement of AP-1 in leptin induced IL-6 production
There are three known cis-regulatory elements such as NF-κB, C/EBP-β, and AP-1 in the promoter region of IL-6 gene . We examined the role of the transcriptional binding sites in induction of IL-6 expression. Three different IL-6 promoter constructs (luc651ΔNF-κB, luc651ΔC/EBP-β, and pIL6-246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
luc651ΔAP-1) were generated by site-directed mutagenesis and testing them in a luciferase reporter assay. We found that leptin-stimulated luciferase activity was abolished by AP-1 binding site mutation, but not by NF-κB or C/EBP-β site mutation (Fig. 5A). The increase in IL-6 expression mediated by leptin was antagonized by AP-1 inhibitor (curcumin) and c-Jun siRNA (Fig. 5B and C). Furthermore, stimulation of OASFs with leptin time-dependently increased c-Jun phosphorylation (Fig. 5D). Pretreatment of cells with Ly294002 and Akt inhibitor or transfection of cells with IRS-1 siRNA markedly inhibited the leptin-induced c-Jun phosphorylation (Fig. 5E).
Furthermore, leptin increased the binding of c-Jun to the AP-1 (312 to 39) element within the IL-6 promoter, as shown by a chromatin immunoprecipitation assay (Fig. 6A). Binding of c-Jun to the AP-1 element was attenuated by OBRl AS-ODN, IRS-1 siRNA, Ly294002, and Akt inhibitor (Fig. 6A). Furthermore, using transient transfection with AP-1-luciferase as an indicator of AP-1 activity showed that OASFs incubated with leptin increase in AP-1 promoter activity (Fig. 6B). The increase of AP-1 activity mediated by leptin was reduced by OBRl AS-ODN, IRS-1 siRNA, p110 siRNA, Akt siRNA, and c-Jun siRNA, or Ly294002, Akt inhibitor, and curcumin (Fig. 6B and C). These data indicated that leptin increased IL-6 production in OASFs via the OBRl, IRS-1, PI3K, Akt, and AP-1 signaling pathway.
Discussion
OA is a heterogeneous group of conditions that are associated with defective integrity of articular cartilage. The chronic inflammatory process is mediated through a complex cytokine network. The factors responsible for initiating the degradation and loss of the articular tissues are not yet completely understood. The level of leptin in the synovial fluid of the joint has been recently shown to be much higher in OA patients compared to control individuals with no history of OA. In fact, leptin levels in the synovial fluid are strongly associated with the radiographic severity of OA , indicating a local effect of leptin in articular cartilage, and further suggesting that leptin levels in the synovial fluid could be used as an effective quantitative marker for detection of OA. First, we found that leptin promoted IL-6 production. In addition, the potentiation of IL-6 by leptin requires activation of the OBRl, IRS-1, PI3K, Akt, and AP-1 signaling pathway. These findings suggest that leptin acts as an inducer of inflammatory cytokines such as IL-6 and enhances the inflammatory response in OA. We previous reported that letpin induced IL-8 expression in human synovial fibroblasts through OBRl/IRS-1/PI3K/Akt/NF-κB pathway . Therefore, both IL-6 and IL-8 are target proteins of the leptin signaling pathway that regulates the cell 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321
inflammatory response. In addition, OBR1/IRS-1/PI3K/Akt is common pathway in leptin-mediated pathogenesis in OA.
The leptin receptor belongs to the cytokine receptor superfamily . Recent studies have demonstrated higher levels of leptin receptors OBRl and OBRs in the synovial fluid and in the cartilage of individuals with OA. It has been reported that leptin receptor expression is significantly elevated in advanced OA cartilage compared to minimally affected cartilage . The results of this study showed that leptin increases the expression of OBRl but not that of OBRs. Furthermore, transfection with OBRl AS-ODN, but not with OBRs AS-AS-ODN, antagonized the leptin-induced IL-6 production. These results suggest that OBRl is an upstream receptor in leptin-induced IL-6 release in human synovial fibroblasts.
Upon leptin binding, OBRl activates IRS proteins and stimulates the IRS-PI3K signaling pathway . In the present study, we used IRS-1 siRNA and found that IRS-1 siRNA inhibited leptin-induced IL-6 production, indicating the possible involvement of IRS-1 in leptin-induced IL-6 release in synovial fibroblasts. It also has been reported that IRS-1 associates with p110, the regulatory subunit of PI3K, to regulate cell functions . Pretreatment of synovial fibroblasts with PI3K inhibitors Ly294002 and wortmannin or transfection with p110 siRNA antagonized the increase of IL-6 expression mediated by leptin. A number of studies have demonstrated that leptin-induced PI3K activation leads to phosphorylation of phosphatidyl inositides and in turn activates the downstream main target Akt, which is an important protein kinase in regulating cell growth, differentiation, adhesion, and inflammatory reactions . In this study, we demonstrated that the leptin-induced expression of IL-6 was inhibited by Akt inhibitor. This was further confirmed by the result that Akt siRNA inhibited the enhancement of IL-6 by leptin. Phosphorylation of Akt was found to be activated by leptin in synovial fibroblasts. These effects were inhibited by IRS-1 siRNA or Ly294002, indicating the involvement of IRS-1/PI3K-dependent Akt activation in leptin-mediated induction of IL-6.
A number of transcription factors, includingNF-κB, CREB, NF-IL-6, and AP-1 box in the5′ region of the IL-6 gene, have severalbinding sites . Recent studies on the IL-6 promoter have demonstrated that IL-6 induction by several transcription factors occurs in a highly stimulus-specific or cell-specific manner . The results of this study showed that AP-1 activation contributes to leptin-induced IL-6 production in synovial fibroblasts, and deletion of AP-1 site reduced leptin-mediated IL-6 promoter activity. Pretreatment of cells with AP-1 inhibitor (curcumin) or c-Jun siRNA also reduced leptin-increased IL-6 production. Therefore, the AP-1 binding site is important in leptin-induced IL-6 production. Furthermore, leptin increased the binding of c-Jun to the AP-1 element on the IL-6 promoter, as shown by the chromatin 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359
immunoprecipitation assay. Using transient transfection with AP-1 luciferase as an indicator of AP-1 activity, we also found that leptin induced an increase in AP-1 activity. In addition, transfection with OBRl AS-ODN, IRS-1 siRNA, p110 siRNA, Akt siRNA, and c-Jun siRNA or pretreatment with Ly294002, Akt inhibitor, and curcumin abolished leptin-increased AP-1 promoter activity. These results indicate that leptin may act through the OBRl receptor, IRS-1, PI3K, Akt, and AP-1 pathway to induce IL-6 activation in human OASFs. In addition to cytokine release, similar pathway has also been reported in the leptin induced IL-6 expression in microglia, which through OBRl/IRS-1/PI3K/Akt/NF-B pathway , and in human synovial fibroblasts leptin promoted IL-8 production, which involved OBRl/IRS-1/PI3K/Akt/NF-B activation . Therefore, OBRl/IRS-1/PI3K/Akt signaling pathway may be a common signaling pathway in leptin-mediated gene expression.
OA is a degenerative joint disease characterized by cartilage breakdown, the formation of bony outgrowths at the joint margin (osteophytes), subchondral bone sclerosis, alterations to the joint capsule, and inflammation of the synovial membrane . Inflammation of the synovium results in synovitis, which can occur in the early stages of OA . Inflamed OA synovial tissue may release inflammatory factors or the damaged cartilage may trigger a systemic inflammatory response, leading to the release of inflammatory mediators by the synovium. Secreted inflammatory factors such as proinflammatory cytokines, therefore, are critical mediators of disturbed metabolism and enhanced catabolism of joint tissue involved in OA. In this study, we investigated the signaling pathway involved in leptin-induced IL-6 production in OASFs. The results showed that leptin increases IL-6 production by binding to the OBRl receptor and activating IRS-1/PI3K/Akt signaling, which enhances AP-1 transcription activity and leads to the transactivation of IL-6 production. On the other hand, leptin is significantly higher in synovial fluid of patients with OA and RA . Therefore, assessing the expression of leptin may be a good marker for prediction of OA and RA.
Acknowledgments
We thank Dr. Oliver Eickelberg for providing IL-6 promoter plasmids. This study was supported by grants from the National Science Council of Taiwan (NSC99-2320-B-039-003-MY3; 100-2320-B-039-028-MY3) and Department of Health Executive Yuan (DOH10220) 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397
Competing interests
The authors have no financial or personal relationships that could inappropriately influence this research.
398 399 400 401
Figure legends
Fig 1. Leptin induces IL-6 expression in human synovial fibroblasts through OBRl receptor
(A and B) OASFs were incubated with various concentrations of leptin for 24 h. Media and total RNA were collected, and the expression of IL-6 was examined by qPCR and ELISA assay (n=4). (C and D) OASFs were incubated with leptin (3 μM) for 6, 12, or 24 h. Media and total RNA were collected, and the expression of IL-6 was examined by qPCR and ELISA assay (n=4). (E) OASFs were incubated with leptin (3 μM) for 24 h. OBRl and OBRs mRNA expression was examined by qPCR (n=4). (F) OASF cells were transfected with OBRl and OBRs AS-ODN or OBRl and OBRs MM-ODN, and mRNA level of OBRl and OBRs was analyzed by qPCR (n=4). (G and H) OASFs were transfected with OBRl and OBRs AS-ODN or OBRl and OBRs MM-ODN for 24 h and then stimulated with leptin (3 μM) for 24 h; IL-6 expression was examined by qPCR and ELISA assay (n=4). Results are expressed as mean ± S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group
Fig 2. The IRS-1 signaling pathway is involved in leptin-mediated increase of IL-6 expression
(A and B) OASFs were transfected with IRS-1 siRNA for 24 h. Media and total RNA were collected, and the expression of IL-6 was examined by qPCR and ELISA assay (n=4). (C) OASFs were incubated with leptin for the indicated time intervals. Total protein was collected and the phosphorylation of IRS-1 was examined by western blotting assay (n=4). (D) OASFs were transfected with OBRl AS-ODN and MM-ODN for 24 h and then stimulated with leptin (3 μM) for 30 min. Total protein was collected and the phosphorylation of IRS-1 was examined by western blotting (n=4). Results are expressed as mean ± S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group
Fig 3. The PI3K signaling pathway is involved in leptin-mediated increase of IL-6 expression
(A and B) OASFs were pretreated for 30 min with Ly294002 and wortmannin or transfected with p110 siRNA for 24 h, followed by stimulation with leptin for 24 h. Media and total RNA were collected, and the expression of IL-6 was 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439
examined by qPCR and ELISA assay (n=4). (C) OASFs were incubated with leptin for the indicated time intervals. Total protein was collected and the phosphorylation of p110 was examined by western blotting (n=4). (D) OASFs were transfected with IRS-1 siRNA for 24 h and then incubated with leptin (3 μM) for 60 min; Total protein was collected and the phosphorylation of p110 was examined by western blotting (n=4). Results are expressed as mean ±S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group
Fig 4. The Akt signaling pathway is involved in the potentiating action of leptin (A and B) OASFs were pretreated for 30 min with Akt inhibitor or transfected with Akt siRNA for 24 h, followed by stimulation with leptin for 24 h. Media and total RNA were collected, and the expression of IL-6 was examined by qPCR and ELISA assay (n=4). (C) OASFs were incubated with leptin for the indicated time intervals. Total protein was collected and the phosphorylation of AKT was examined by western blotting (n=4). (D) OASFs were pretreated for 30 min with Ly294002 or transfected with IRS-1 siRNA for 24 h and then incubated with leptin (3 μM) for 60 min; Total protein was collected and the phosphorylation of AKT was examined by western blotting (n=4). Results are expressed as mean ±S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group
Fig 5. Involvement of AP-1 in leptin induced IL-6 production
(A) OASFs were transfected with indicated IL-6 promoter luciferase plasmids for 24 h. Cells were than incubated with leptin (3 μM) for 24 h. IL-6 luciferase activity was measured, and the results were normalized to -galactosidase activity and expressed as the mean ± SE for 3 independent experiments performed in triplicate (n=4). (B and C) OASFs were pretreated for 30 min with curcumin or transfected for 24 h with c-Jun siRNA, followed by stimulation with leptin for 24 h. Media and total RNA were collected, and the expression of IL-6 was examined by qPCR and ELISA assay (n=4). (D) OASFs were incubated with leptin for the indicated time intervals. Total protein was collected and the phosphorylation of c-Jun was examined by western blotting (n=4). (E) OASFs were pretreated with Ly294002 and Akt inhibitor for 30 min or transfected with IRS-1 siRNA for 24 h and then incubated with leptin for 120 min. Total protein was collected and the phosphorylation of c-Jun was examined by western blotting (n=4). Results are 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477
expressed as mean ±S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group.
Fig 6. Leptin induces AP-1 activation through OBRl receptor/IRS-1/PI3K/Akt pathway.
(A) OASFs were pretreated with Ly294002 and Akt inhibitor for 30 min or transfected with OBRl AS-ODN and IRS-1 siRNA for 24 h and then stimulated with leptin for 120 min, and chromatin immunoprecipitation assay was performed. Chromatin was immunoprecipitated with anti-c-Jun. One percent of the precipitated chromatin was assayed to verify equal loading (input) (n=4). (B and C) OASFs were transfected with AP-1-luciferase expression vector and then pretreated with Ly294002, Akt inhibitor, and curcumin or cotransfected with OBRl AS-ODN, IRS-1 siRNA, p110 siRNA, Akt siRNA, and c-Jun siRNA before incubation with leptin for 24 h. Luciferase activity was then assayed. Results are expressed as mean ±S.E.M. of four independent experiments. *: p < 0.05 as compared with basal level. #: p < 0.05 as compared with the leptin-treated group
478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495
References
1. Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB (2013) Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol 25: 136-144.
2. Gkretsi V, Simopoulou T, Tsezou A (2011) Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res 50: 133-140.
3. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H (2011) Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 7: 33-42.
4. Livshits G, Zhai G, Hart DJ, Kato BS, Wang H, et al. (2009) Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum 60: 2037-2045.
5. Graeve L, Baumann M, Heinrich PC (1993) Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. Clin Investig 71: 664-671.
6. Grimble RF (1998) Nutritional modulation of cytokine biology. Nutrition 14: 634-640.
7. Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, et al. (2000) Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 6: 71-79.
8. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, et al. (1998) The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 41: 1760-1771.
9. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, et al. (2001) Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 44: 1620-1632.
10. Sui Y, Lee JH, DiMicco MA, Vanderploeg EJ, Blake SM, et al. (2009) Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage. Arthritis Rheum 60: 2985-2996.
11. Poree B, Kypriotou M, Chadjichristos C, Beauchef G, Renard E, et al. (2008) Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533
factors to the COL2A1 promoter. J Biol Chem 283: 4850-4865.
12. Pelletier JP, Raynauld JP, Caron J, Mineau F, Abram F, et al. (2010) Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 69: 2095-2101.
13. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
14. Elmquist JK, Maratos-Flier E, Saper CB, Flier JS (1998) Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1: 445-450.
15. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, et al. (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252.
16. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, et al. (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271.
17. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, Bidlingmaier M, Wu Z, et al. (2001) High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 167: 4593-4599.
18. Sweeney G (2002) Leptin signalling. Cell Signal 14: 655-663.
19. Marks R, Allegrante JP (2002) Body mass indices in patients with disabling hip osteoarthritis. Arthritis Res 4: 112-116.
20. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, et al. (2003) Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 48: 3118-3129.
21. Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, et al. (2003) Adipocytokines in synovial fluid. JAMA 290: 1709-1710.
22. Palmer G, Gabay C (2003) A role for leptin in rheumatic diseases? Ann Rheum Dis 62: 913-915.
23. Busso N, So A, Chobaz-Peclat V, Morard C, Martinez-Soria E, et al. (2002) Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 168: 875-882.
24. Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM (2007) Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol 179: 5483-534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571
5492.
25. Tang CH, Hsu CJ, Fong YC (2010) The CCL5/CCR5 axis promotes interleukin-6 production in human synovial fibroblasts. Arthritis and rheumatism 62: 3615-3624.
26. Liu JF, Hou SM, Tsai CH, Huang CY, Hsu CJ, et al. (2013) CCN4 induces vascular cell adhesion molecule-1 expression in human synovial fibroblasts and promotes monocyte adhesion. Biochimica et biophysica acta 1833: 966-975.
27. Huang CY, Chen SY, Tsai HC, Hsu HC, Tang CH (2012) Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. Arthritis and rheumatism 64: 3344-3354.
28. Chiu YC, Lin CY, Chen CP, Huang KC, Tong KM, et al. (2009) Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1- dependent pathway. J Immunol 183: 2785-2792.
29. Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, et al. (2006) Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 14: 690-695.
30. Del Rey MJ, Izquierdo E, Usategui A, Gonzalo E, Blanco FJ, et al. (2010) The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 62: 3584-3594.
31. Bao JP, Chen WP, Feng J, Hu PF, Shi ZL, et al. (2010) Leptin plays a catabolic role on articular cartilage. Mol Biol Rep 37: 3265-3272.
32. Simopoulou T, Malizos KN, Iliopoulos D, Stefanou N, Papatheodorou L, et al. (2007) Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage 15: 872-883.
33. Metlakunta AS, Sahu M, Yasukawa H, Dhillon SS, Belsham DD, et al. (2011) Neuronal suppressor of cytokine signaling-3 deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase signaling. Am J Physiol Regul Integr Comp Physiol 300: R1185-1193. 34. Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA (2004)
Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 145: 4103-4112.
35. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG, Jr., et al. 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609
(2001) Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 413: 794-795.
36. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, et al. (2000) Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287: 1049-1053.
37. Grassl C, Luckow B, Schlondorff D, Dendorfer U (1999) Transcriptional regulation of the interleukin-6 gene in mesangial cells. J Am Soc Nephrol 10: 1466-1477.
38. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, et al. (1993) Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 90: 10193-10197.
39. Ku JH, Lee CK, Joo BS, An BM, Choi SH, et al. (2009) Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin Rheumatol 28: 1431-1435.
40. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, et al. (2008) Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cellular signalling 20: 1478-1488.
41. Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68: 437-446.
42. Chattopadhyay M, Selinger ES, Ballou LM, Lin RZ (2011) Ablation of PI3K p110-alpha prevents high-fat diet-induced liver steatosis. Diabetes 60: 1483-1492.
43. Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, et al. (2000) Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 14: 2329-2338.
44. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, et al. (2002) Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51: 168-173. 45. Persson E, Voznesensky OS, Huang YF, Lerner UH (2005) Increased
expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-kappaB, in mouse calvarial osteoblasts. Bone 37: 513-529.
46. Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC, et al. (2007) Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647
pathway in microglia. Journal of immunology 179: 1292-1302.
47. Samuels J, Krasnokutsky S, Abramson SB (2008) Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 66: 244-250.
48. Sellam J, Berenbaum F (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 6: 625-635. 648 649 650 651 652 653 654
